TNFRSF10B and neoplasm: Unexpectedly for a resistant model, instead of a slight decrease or an absence of response to DR5 agonist, the group injected with AMG655 presented an accelerated tumor growth with a tumor volume significantly higher at D30, and up to 30% higher compared to the control group at D37 (Figure 2C).